6.2 Benign Prostatic Hyperplasia & Erectile Dysfunction

Benign Prostatic Hyperplasia & Erectile Dysfunction

Executive Summary: Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED) are highly prevalent, interconnected urological conditions in aging men that frequently coexist and severely impair quality of life. For the Board Certified Ambulatory Care Pharmacist (BCACP), optimal clinical management requires utilizing the International Prostate Symptom Score (IPSS) to triage dynamic vs. static bladder outlet obstruction, navigating the safety nuances of non-selective vs. uroselective alpha-1 blockers (including Intraoperative Floppy Iris Syndrome), executing long-term disease modification with 5-alpha reductase inhibitors (5-ARIs) under strict PSA monitoring rules, mastering PDE5 inhibitor kinetics, and enforcing absolute contraindications with organic nitrates.

1. AUA BPH Guidelines, Pathophysiology & IPSS Diagnostic Stratification

Dual Pathophysiology of Bladder Outlet Obstruction (BOO)

BPH involves non-malignant cellular proliferation of both glandular epithelial and stromal smooth muscle elements within the periurethral transition zone of the prostate. Bladder outlet obstruction arises from two distinct, compounding components:

1. Dynamic (Functional) Obstruction: Mediated by increased sympathetic alpha-1 adrenergic tone in the prostatic stroma, prostatic capsule, and bladder neck.
2. Static (Physical / Mechanical) Obstruction: Mediated by physical mechanical mass enlargement of the prostate gland impinging on the prostatic urethra, driven by androgenic stimulation via dihydrotestosterone (DHT).

Symptom Spectrum: Storage vs. Voiding

Lower Urinary Tract Symptoms (LUTS) secondary to BPH are divided into:

• Storage (Irritative) Symptoms: Frequency, nocturia, urgency, urge incontinence (caused by secondary bladder detrusor muscle hypertrophy, instability, and decreased compliance).
• Voiding (Obstructive) Symptoms: Hesitancy, weak or intermittent urinary stream, terminal dribbling, straining to void, sensation of incomplete bladder emptying.

The International Prostate Symptom Score (IPSS)

The American Urological Association (AUA) validates the IPSS / AUA-Symptom Index (AUA-SI), comprising 7 urinary symptom questions (each scored 0 to 5) plus 1 global disease-specific quality of life question (Total score: 0 to 35 points).

2. Alpha-1 Adrenergic Receptor Antagonists: Rapid Functional De-Obstruction

Alpha-1 blockers act on the dynamic component of BPH by competitively antagonizing alpha-1 adrenergic receptors located on prostatic and bladder neck smooth muscle. This induces relaxation, reduces urethral resistance, and increases peak urinary flow rate (by 2–3 mL/sec) and improves IPSS by 4–6 points within 1 to 2 weeks. Crucially, alpha-blockers do NOT alter prostate size or reduce the long-term risk of acute urinary retention or surgery.

Non-Selective vs. Uroselective Alpha-1 Blockers

3. Intraoperative Floppy Iris Syndrome (IFIS)

Intraoperative Floppy Iris Syndrome (IFIS) is a critical surgical complication characterized by a classic intraoperative triad during cataract phacoemulsification surgery:

1. Flaccid, billowing iris stroma that undulates with normal irrigation currents.
2. Progressive, involuntary intraoperative pupillary constriction (miosis) despite preoperative mydriatics.
3. Prolapse of the iris toward the phacoemulsification and side-port incisions.

                                   IFIS PATHOPHYSIOLOGIC MECHANISM
                                   
    Alpha-1A Adrenergic Antagonist (e.g., Tamsulosin, Silodosin, Terazosin)
                         │
                         ▼
    Long-Term / Irreversible Blockade of Alpha-1A Receptors on Iris Dilator Muscle
                         │
                         ▼
    Iris Dilator Muscle Tone Loss & Muscular Atrophy
                         │
                         ▼
    Cataract Extraction Surgery (Pupil constricts, iris billows, iris prolapses into corneal wound)
                         │
                         ▼
    Complications: Posterior Capsule Rupture, Vitreous Loss, Permanent Visual Impairment

Key Ambulatory Practice Pearls for IFIS

• Permanent / Durable Structural Alteration: IFIS can occur even if the alpha-blocker was discontinued weeks, months, or years prior to surgery, or even after a brief exposure (as few as 1 to 2 doses).
• Mandatory Preoperative Screening: Prior to initiating any alpha-1 blocker (especially tamsulosin or silodosin), the ambulatory care pharmacist must ask: "Are you currently planning or scheduled to have cataract or glaucoma surgery?"
• Actionable Steps:
  • If cataract surgery is planned in the near future, defer starting the alpha-blocker until after the ophthalmologist completes the surgery.
  • If the patient is already taking an alpha-blocker, do NOT abruptly stop the drug without consulting the ophthalmologist (discontinuation does not eliminate IFIS risk and can precipitate urinary retention). Instead, ensure the patient explicitly informs their eye surgeon so the surgeon can utilize iris retractors, pupillary expansion rings (Malyugin rings), or intracameral epinephrine.

4. 5-Alpha Reductase Inhibitors (5-ARIs): Disease-Modifying Static Regression

5-Alpha Reductase Inhibitors (5-ARIs) target the static mechanical component of BPH by blocking the intracellular conversion of testosterone to its active metabolite, dihydrotestosterone (DHT), which has a 5-fold higher affinity for the androgen receptor than testosterone and drives prostatic epithelial hyperplasia.

Agent Comparison: Finasteride vs. Dutasteride

Clinical Indication & Disease Modification

• Patient Selection Criteria: 5-ARIs are indicated ONLY in men with demonstrable prostatic enlargement (> 30 grams on ultrasound/DRE) or elevated baseline serum PSA (> 1.5 ng/mL). They have minimal efficacy in men with normal-sized prostates (< 30 g).
• True Disease-Modifying Efficacy: Landmark long-term trials (PLESS, MTOPS, CombAT) demonstrated that 5-ARIs shrink prostate gland volume by 20% to 30%, increase peak flow by 1.5–2 mL/sec, and reduce the long-term risk of Acute Urinary Retention (AUR) by ~57% and the need for BPH-related surgical resection (TURP) by ~55%.
• Delayed Onset of Benefit: Maximal clinical prostate regression and symptom reduction requires 6 to 12 months of continuous therapy. Patients must be counseled that 5-ARIs do not provide immediate overnight relief.

The "Rule of Double" for Prostate Cancer Screening (PSA)

• 50% PSA Suppression: Continuous therapy with a 5-ARI reduces total serum Prostate-Specific Antigen (PSA) levels by approximately 50% after 6 months.
• The Rule of Double: In any patient who has taken finasteride or dutasteride for ≥ 6 months, the clinician MUST MULTIPLY THE REPORTED SERUM PSA VALUE BY 2 (or establish a new post-treatment PSA nadir) when evaluating for prostate cancer.
• Clinical Significance: If a patient on chronic 5-ARI therapy has a measured PSA of 2.5 ng/mL, their adjusted clinical PSA is 5.0 ng/mL (exceeding the typical 4.0 ng/mL screening threshold). Any confirmed increase in PSA from the lowest on-treatment nadir warrants prompt urological evaluation to rule out high-grade prostate adenocarcinoma.

Teratogenicity & Safe Handling Protocol (Category X)

• Teratogenic Mechanism: Exposure of a developing male fetus to 5-ARIs inhibits DHT-dependent development of male external genitalia, resulting in hypospadias, cryptorchidism, micropenis, and ambiguous genitalia.
• Mandatory Patient & Caregiver Counseling: Women who are pregnant or who may become pregnant must NEVER handle crushed or broken tablets of finasteride or leaking capsules of dutasteride. Absorption occurs readily through the skin. If contact occurs, wash immediately with soap and water.
• Sexual Adverse Effects: Decreased libido (3–5%), erectile dysfunction (5–8%), ejaculatory dysfunction (1–2%), and gynecomastia/breast tenderness (~1%).

5. Combination Pharmacotherapy & PDE5 Inhibitor Dual Therapy for BPH

Alpha-Blocker + 5-ARI Combination Therapy

• Rationale: Merges the rapid symptom relief of an alpha-1 blocker (acting within 1–2 weeks on smooth muscle tone) with the long-term anatomical regression and disease modification of a 5-ARI (reducing surgery/AUR over 6–12+ months).
• Landmark Evidence: The MTOPS trial (finasteride + doxazosin) and CombAT trial (dutasteride + tamsulosin producing the fixed-dose combination Jalyn 0.5 mg / 0.4 mg daily) proved that dual combination therapy is significantly superior to either monotherapy in preventing clinical progression (AUR, invasive surgery, and IPSS symptom worsening).
• Target Population: Men with moderate-to-severe symptoms (IPSS ≥ 8) AND enlarged prostate (≥ 30 g or PSA ≥ 1.5 ng/mL).

Phosphodiesterase-5 (PDE5) Inhibitors in BPH Management

• Agent: Tadalafil (Cialis) 5 mg orally once daily is FDA-approved for the treatment of signs and symptoms of BPH, both as monotherapy and for concurrent BPH and Erectile Dysfunction.
• Mechanism: Inhibits PDE5 in prostatic smooth muscle, bladder neck, and pelvic vasculature, increasing intracellular cyclic guanosine monophosphate (cGMP). This promotes smooth muscle relaxation, decreases detrusor overactivity, improves pelvic perfusion, and downregulates bladder afferent nerve firing.
• Clinical Profile: Tadalafil significantly improves IPSS score by 2–4 points and treats comorbid ED. However, unlike alpha-blockers, tadalafil does NOT significantly increase peak urinary flow rate or reduce prostate volume.

6. Erectile Dysfunction (ED) Pharmacotherapy & PDE5 Inhibitor Pharmacology

Erectile Dysfunction is defined as the consistent or recurrent inability to attain and/or maintain a penile erection of sufficient rigidity to permit satisfactory sexual intercourse.

Physiology of Penile Erection & The NO-cGMP Pathway

1. Sexual arousal triggers parasympathetic activation and non-adrenergic non-cholinergic (NANC) neural firing, releasing Nitric Oxide (NO) from cavernous nerve terminals and endothelial cells.
2. NO diffuses into adjacent trabecular vascular smooth muscle cells, activating soluble Guanylate Cyclase (sGC).
3. sGC converts GTP into cyclic Guanosine Monophosphate (cGMP).
4. cGMP activates protein kinase G, dephosphorylating myosin light chains, causing intracellular calcium efflux and profound smooth muscle relaxation. Sinusoids engorge with arterial blood, compressing the subtunical venules against the rigid tunica albuginea (veno-occlusion), producing erection.
5. Phosphodiesterase Type 5 (PDE5) degrades cGMP into inactive 5'-GMP, leading to detumescence.

Comparative Pharmacokinetics & Pharmacology of Oral PDE5 Inhibitors

7. Critical Drug Interactions: Nitrates & Alpha-Blocker Co-Administration

Absolute Contraindication: Co-Administration with Organic Nitrates

Co-administration of any PDE5 inhibitor with organic nitrates is STRICTLY AND ABSOLUTELY CONTRAINDICATED.

• Pathophysiologic Mechanism: Nitrates act as exogenous nitric oxide donors that massively generate cGMP, while PDE5 inhibitors completely block cGMP breakdown. This causes a synergistic accumulation of intracellular cGMP, producing catastrophic systemic vasodilation, profound refractory hypotension, coronary hypoperfusion, myocardial infarction, and cardiovascular collapse.
• Prohibited Nitrate Formulations: Sublingual nitroglycerin tablets/spray, oral isosorbide mononitrate/dinitrate, transdermal nitroglycerin patches, intravenous nitroglycerin, and recreational inhaled alkyl nitrites ("poppers").

Mandatory Nitrate Washout Periods Before Emergency Nitrate Use

If a patient taking an oral PDE5 inhibitor develops acute ischemic chest pain, organic nitrates must NOT be administered within the following strict timeframes:

+---------------------------------------------------------------------------------------+
|                      MANDATORY NITRATE WASHOUT TIME WINDOWS                           |
+------------------------------------+--------------------------------------------------+
| PDE5 Inhibitor Ingested            | Minimum Mandatory Washout Before Any Nitrate     |
+------------------------------------+--------------------------------------------------+
| Sildenafil (Viagra)                | At least 24 Hours                                |
+------------------------------------+--------------------------------------------------+
| Vardenafil (Levitra)               | At least 24 Hours                                |
+------------------------------------+--------------------------------------------------+
| Avanafil (Stendra)                 | At least 12 Hours                                |
+------------------------------------+--------------------------------------------------+
| Tadalafil (Cialis)                 | At least 48 Hours                                |
+------------------------------------+--------------------------------------------------+

Clinical Management in Acute Coronary Syndrome (ACS): If a patient presents with an acute myocardial infarction within these prohibition windows, nitrates are withheld. The clinical team must rely entirely on non-nitrate anti-ischemic and hemodynamic agents: intravenous beta-blockers, morphine/fentanyl, supplemental oxygen, aspirin, P2Y12 inhibitors, unfractionated heparin/LMWH, and emergency percutaneous coronary intervention (PCI).

Safe Co-Administration with Alpha-1 Adrenergic Blockers

Both alpha-blockers and PDE5 inhibitors induce vasodilation, creating a risk of additive orthostatic hypotension and syncope. To safely combine these agents:

1. Hemodynamic Stability First: The patient must be hemodynamically stable on one medication class before introducing the other.
2. Start at Lowest Doses: Initiate the second agent at the lowest possible starting dose (e.g., sildenafil 25 mg or tadalafil 2.5–5 mg).
3. Prioritize Uroselective Alpha-Blockers: Uroselective agents (tamsulosin 0.4 mg daily) have minimal vascular alpha-1B affinity and have the lowest propensity for hypotensive interactions compared to non-selective agents (terazosin, doxazosin).
4. Separate Administration Times: When co-prescribing a non-selective alpha-blocker with a PRN PDE5 inhibitor, separate dosing times by at least 4 to 6 hours.